Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Atul Dandekar sold 7,500 shares of the stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $27.58, for a total transaction of $206,850.00. Following the sale, the insider owned 26,250 shares in the company, valued at approximately $723,975. This trade represents a 22.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Atul Dandekar also recently made the following trade(s):
- On Wednesday, July 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.34, for a total transaction of $205,050.00.
- On Monday, June 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $28.02, for a total value of $210,150.00.
Maze Therapeutics Stock Down 3.2%
Shares of NASDAQ MAZE opened at $26.57 on Tuesday. The stock has a market cap of $1.48 billion, a P/E ratio of -10.54 and a beta of 2.22. The business's fifty day simple moving average is $28.76 and its 200-day simple moving average is $31.63. Maze Therapeutics, Inc. has a 12-month low of $13.89 and a 12-month high of $53.65. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting the consensus estimate of ($0.76). As a group, equities analysts predict that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms recently weighed in on MAZE. BTIG Research restated a "buy" rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Wall Street Zen downgraded shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Finally, TD Cowen upgraded shares of Maze Therapeutics to a "strong-buy" rating in a report on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Maze Therapeutics currently has an average rating of "Buy" and a consensus price target of $66.00.
Get Our Latest Stock Analysis on MAZE
Institutional Investors Weigh In On Maze Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in MAZE. TRV GP IV LLC purchased a new stake in Maze Therapeutics during the second quarter worth approximately $133,502,907. ARCH Venture Management LLC acquired a new stake in Maze Therapeutics during the second quarter worth approximately $122,983,582. BlackRock Inc. acquired a new stake in Maze Therapeutics during the second quarter worth approximately $104,525,000. Jupiter Topco LLC purchased a new stake in shares of Maze Therapeutics during the 2nd quarter worth approximately $101,764,000. Finally, Janus Henderson Group PLC boosted its holdings in shares of Maze Therapeutics by 318.0% in the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company's stock valued at $130,197,000 after buying an additional 2,390,713 shares in the last quarter.
About Maze Therapeutics
(
Get Free Report)
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
